We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Axsome (AXSM) Surges on Potential Approval for AXS-05 Soon
Read MoreHide Full Article
Axsome Therapeutics, Inc. (AXSM - Free Report) announced that it has received post-marketing requirements/commitments proposed by the FDA related to its new drug application (“NDA”) seeking approval for one of its lead candidates, AXS-05. The company has also agreed to the FDA’s proposal.
The NDA is seeking approval for AXS-05 as a potential treatment for major depressive disorder (“MDD”). Following this new regulatory update related to the AXS-05 NDA, the company believes that the FDA may provide a decision during the second quarter.
Axsome’s shares gained 25.1% on Apr 19, following the receipt of proposed post-marketing requirements/commitments from the FDA. In fact, shares of Axsome have gained 8.3% so far this year against the industry’s decline of 15.6%.
Image Source: Zacks Investment Research
Axsome filed the NDA for AXS-05 in 2021, which was granted priority review by the FDA. A decision was previously expected in August 2021. However, the FDA extended the review period for the NDA in August last year, citing deficiencies within the NDA that preclude labeling discussions, including deficiencies related to analytical methods in the chemistry, manufacturing, and controls section of the NDA. The regulatory authority informed the company that it will not be able to take action related to the NDA until the deficiencies are addressed.
On its fourth-quarter earnings call, Axsome stated that it has already submitted a response to these deficiencies, which have been duly received by the FDA. AXSM stated that the responses filed by it are not major amendments to the NDA.
Investors cheered the recent update from the FDA amid uncertainty related to the review timeline for the AXS-05 NDA for MDD. A potential approval will lead to the first commercialized product for Axsome.
The company has been actively engaged in preparing for the commercial launch of AXS-05 targeting MDD patients in the past few months regardless of the extension of the review timeline for its NDA.
Apart from MDD, Axsome is also developing AXS-05 for treating treatment-resistant depression (“TRD”), smoking cessation and agitation associated with Alzheimer's disease (“AD”). The company is currently enrolling patients in the phase III ACCORD study, which is evaluating the safety and efficacy of AXS-05 for treating agitation associated with AD. It plans to start a pivotal phase II/III study for AXS-05 as a potential treatment for smoking cessation. The timing of the initiation will be informed later this year.
In a bid to strengthen its portfolio, Axsome signed an agreement with Jazz Pharmaceuticals (JAZZ - Free Report) last month to acquire the latter’s new sleep drug, Sunosi.
Jazz has received approval for Sunosi as a treatment to improve wakefulness and reduce excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea. Jazz currently commercializes Sunosi in the United States, Europe and several other countries.
The Zacks Consensus Estimate for Axcella Health’s 2022 and 2023 loss has narrowed 12.9% and 16.4%, respectively, over the past 60 days. AXLA has declined 6.2% so far this year.
Earnings of Axcella Health surpassed estimates in three of the trailing four quarters and missed once, the average beat being 1.67%.
The consensus estimate for Trevi’s 2022 bottom line has narrowed 19.4% for 2022 and 14.1% for 2023 over the past 60 days. The stock has surged 328.3% so far this year.
Earnings of Trevi surpassed estimates in two of the trailing four quarters and missed the same on the other two occasions, the average beat being 5.09%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Axsome (AXSM) Surges on Potential Approval for AXS-05 Soon
Axsome Therapeutics, Inc. (AXSM - Free Report) announced that it has received post-marketing requirements/commitments proposed by the FDA related to its new drug application (“NDA”) seeking approval for one of its lead candidates, AXS-05. The company has also agreed to the FDA’s proposal.
The NDA is seeking approval for AXS-05 as a potential treatment for major depressive disorder (“MDD”). Following this new regulatory update related to the AXS-05 NDA, the company believes that the FDA may provide a decision during the second quarter.
Axsome’s shares gained 25.1% on Apr 19, following the receipt of proposed post-marketing requirements/commitments from the FDA. In fact, shares of Axsome have gained 8.3% so far this year against the industry’s decline of 15.6%.
Image Source: Zacks Investment Research
Axsome filed the NDA for AXS-05 in 2021, which was granted priority review by the FDA. A decision was previously expected in August 2021. However, the FDA extended the review period for the NDA in August last year, citing deficiencies within the NDA that preclude labeling discussions, including deficiencies related to analytical methods in the chemistry, manufacturing, and controls section of the NDA. The regulatory authority informed the company that it will not be able to take action related to the NDA until the deficiencies are addressed.
On its fourth-quarter earnings call, Axsome stated that it has already submitted a response to these deficiencies, which have been duly received by the FDA. AXSM stated that the responses filed by it are not major amendments to the NDA.
Investors cheered the recent update from the FDA amid uncertainty related to the review timeline for the AXS-05 NDA for MDD. A potential approval will lead to the first commercialized product for Axsome.
The company has been actively engaged in preparing for the commercial launch of AXS-05 targeting MDD patients in the past few months regardless of the extension of the review timeline for its NDA.
Apart from MDD, Axsome is also developing AXS-05 for treating treatment-resistant depression (“TRD”), smoking cessation and agitation associated with Alzheimer's disease (“AD”). The company is currently enrolling patients in the phase III ACCORD study, which is evaluating the safety and efficacy of AXS-05 for treating agitation associated with AD. It plans to start a pivotal phase II/III study for AXS-05 as a potential treatment for smoking cessation. The timing of the initiation will be informed later this year.
In a bid to strengthen its portfolio, Axsome signed an agreement with Jazz Pharmaceuticals (JAZZ - Free Report) last month to acquire the latter’s new sleep drug, Sunosi.
Jazz has received approval for Sunosi as a treatment to improve wakefulness and reduce excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea. Jazz currently commercializes Sunosi in the United States, Europe and several other countries.
Axsome Therapeutics, Inc. Price
Axsome Therapeutics, Inc. price | Axsome Therapeutics, Inc. Quote
Zacks Rank & Stocks to Consider
Axsome currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the biotech sector are Axcella Health and Trevi Therapeutics (TRVI - Free Report) , both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Axcella Health’s 2022 and 2023 loss has narrowed 12.9% and 16.4%, respectively, over the past 60 days. AXLA has declined 6.2% so far this year.
Earnings of Axcella Health surpassed estimates in three of the trailing four quarters and missed once, the average beat being 1.67%.
The consensus estimate for Trevi’s 2022 bottom line has narrowed 19.4% for 2022 and 14.1% for 2023 over the past 60 days. The stock has surged 328.3% so far this year.
Earnings of Trevi surpassed estimates in two of the trailing four quarters and missed the same on the other two occasions, the average beat being 5.09%.